$50.79 Million in Sales Expected for Tilray Inc (NASDAQ:TLRY) This Quarter

Analysts predict that Tilray Inc (NASDAQ:TLRY) will report sales of $50.79 million for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Tilray’s earnings, with the lowest sales estimate coming in at $40.00 million and the highest estimate coming in at $56.10 million. Tilray posted sales of $10.05 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 405.4%. The company is expected to issue its next quarterly earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Tilray will report full-year sales of $177.86 million for the current year, with estimates ranging from $144.80 million to $199.00 million. For the next financial year, analysts forecast that the company will report sales of $386.93 million, with estimates ranging from $326.54 million to $601.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Tilray.

Tilray (NASDAQ:TLRY) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.09). Tilray had a negative return on equity of 37.64% and a negative net margin of 121.73%. The firm had revenue of $45.90 million for the quarter, compared to the consensus estimate of $40.25 million. During the same period last year, the firm earned ($0.17) EPS. The company’s revenue for the quarter was up 373.2% on a year-over-year basis.



Several equities research analysts have issued reports on the company. Oppenheimer assumed coverage on Tilray in a research note on Tuesday, June 4th. They set a “market perform” rating for the company. Consumer Edge assumed coverage on Tilray in a research note on Friday, June 28th. They set an “overweight” rating and a $54.00 price target for the company. MKM Partners assumed coverage on Tilray in a research note on Thursday, September 19th. They set a “neutral” rating and a $34.00 price target for the company. Compass Point dropped their price target on Tilray from $41.00 to $38.00 and set a “sell” rating for the company in a research note on Monday, June 17th. Finally, Cowen set a $60.00 price target on Tilray and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $55.14.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLRY. ETF Managers Group LLC purchased a new position in Tilray during the 2nd quarter valued at about $92,004,000. Zevenbergen Capital Investments LLC increased its holdings in Tilray by 37.1% during the 1st quarter. Zevenbergen Capital Investments LLC now owns 730,280 shares of the company’s stock valued at $47,848,000 after purchasing an additional 197,540 shares during the period. Think Investments LP purchased a new position in Tilray during the 2nd quarter valued at about $7,031,000. Morgan Stanley increased its holdings in Tilray by 44.2% during the 2nd quarter. Morgan Stanley now owns 330,527 shares of the company’s stock valued at $15,390,000 after purchasing an additional 101,375 shares during the period. Finally, Vanguard Group Inc. purchased a new position in Tilray during the 2nd quarter valued at about $3,484,000. 7.63% of the stock is owned by institutional investors.

TLRY stock traded down $0.13 during mid-day trading on Friday, hitting $26.60. 1,043,335 shares of the stock were exchanged, compared to its average volume of 2,014,022. The company has a debt-to-equity ratio of 1.21, a current ratio of 2.04 and a quick ratio of 1.61. The business has a fifty day moving average price of $31.99 and a 200 day moving average price of $45.64. Tilray has a 12 month low of $25.15 and a 12 month high of $178.85. The stock has a market capitalization of $2.60 billion, a price-to-earnings ratio of -32.44 and a beta of 4.54.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Read More: Determine Your Level of Risk Tolerance

Get a free copy of the Zacks research report on Tilray (TLRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.